TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.


Options:
A: Arm Label: Perampanel; Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Perampanel; Assigned to Arm(s): Perampanel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Perampanel; Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: Perampanel; Assigned to Arm(s): Perampanel | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo-Controlled Study of Perioperative Administration of Olanzapine to Prevent Postoperative Delirium in Joint Replacement Patients
Brief Summary: In this study we wanted to determine if perioperative administration of olanzapine prior to knee or hip replacement surgery in high risk patients would prevent the onset of postoperative delirium.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: donepezil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rivastigmine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivastigmine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Deeper sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Deeper sedation | Arm Label: Moderate sedation; Type: ACTIVE_COMPARATOR; Interventions: Device: Moderate sedation | Intervention Type: DEVICE; Name: Deeper sedation; Assigned to Arm(s): Deeper sedation | Intervention Type: DEVICE; Name: Moderate sedation; Assigned to Arm(s): Moderate sedation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Brief Summary: The purpose of this study is to evaluate the safety, efficacy and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: perampanel | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: perampanel | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: perampanel | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: perampanel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: perampanel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: perampanel; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: Perampanel; Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Perampanel; Assigned to Arm(s): Perampanel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Perampanel; Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: Perampanel; Assigned to Arm(s): Perampanel | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed
Brief Summary: This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is, patients who are not managed with acute coronary revascularization).


Options:
A: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel, Drug: Commercially-available Aspirin | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel, Drug: Commercially-available Aspirin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Commercially-available Aspirin; Assigned to Arm(s): Clopidogrel, Prasugrel
B: Arm Label: Standard Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet, Behavioral: Exercise, Behavioral: Stop smoking, Drug: Glucose lowering therapy, Drug: Blood pressure lowering therapy, Drug: Lipid lowering therapy | Arm Label: Intensive Treatment Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Behavioral: Stop smoking, Drug: Glucose lowering therapy, Drug: Blood pressure lowering therapy, Drug: Lipid lowering therapy | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: BEHAVIORAL; Name: Stop smoking; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Glucose lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Blood pressure lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Lipid lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: No aspirin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: No aspirin; Assigned to Arm(s): 2
D: Arm Label: Aggrenox; Type: EXPERIMENTAL; Interventions: Drug: Aggrenox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AID-trial:A Randomized Clinical Trial Comparing the Effect on Repeated Self-harm of Assertive Intervention and Standard Treatment After Deliberate Self-harm
Brief Summary: Background

Previous suicide attempts is a high-risk factor with a repetition rate between 12-30 percent. Compliance with after treatment is often poor. A systematic review by Hawton, 1999 states a lack of evidence on psychosocial interventions due to selections bias or statistical power.

Objective

The aim is to investigate if assertive outreach, incorporating hands-on guidance and motivational support of compliance with follow-up treatment after suicide attempts is able to reduce the frequency of non-fatal and fatal suicide acts in a one-year follow-up period.

Method and Design

A randomized, controlled intervention trial in a prospective design. The patients included will be randomized to either standard treatment (n = 120) or intervention treatment (N = 120), representing 6 - 8 assertive outreach contacts with a research nurse after suicide attempts or deliberate self-harm. The outreach contacts are thought of as supporting and guiding home visits towards compliance with after care or follow-up treatment Inclusion criteria Males and females, aged 12 years or older with a recent suicide attempt or act of deliberate self-harm, living independently and not diagnosed with severe mental illness (psychosis, severe dementia)

Outcome

The primary outcome measure is repeated fatal suicidal act (fatal or non fatal)assessed by the Danish Cause of Death Register and the rate of repeated suicide attempts/deliberate self-harm registered in the medical records by the collaborating wards and units in their routine procedure of treating people applying for help in relation to suicidal behavior.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive training | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive training | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): 1, 2
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Assertive intervention | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard treatment | Intervention Type: BEHAVIORAL; Name: Assertive intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): B
C: Arm Label: Case management; Type: EXPERIMENTAL; Interventions: Behavioral: Case management | Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Case management; Assigned to Arm(s): Case management | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care
D: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination
Brief Summary: This study will evaluate the efficacy and safety of adding bevacizumab to crossover fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer who have experienced disease progression under first line treatment with standard chemotherapy plus bevacizumab. Participants will receive chemotherapy alone, or in combination with bevacizumab. The anticipated time on study treatment is until disease progression or unacceptable toxicity occurs. Participants are allowed to continue on bevacizumab, even after stopping chemotherapy.


Options:
A: Arm Label: TAS-102; Type: EXPERIMENTAL; Interventions: Drug: TAS-102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TAS-102; Assigned to Arm(s): TAS-102 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy, Drug: Bevacizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab
C: Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI
D: Arm Label: 5-Fluorouracil (5-FU); Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU | Arm Label: Capecitabine; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine | Intervention Type: DRUG; Name: 5-FU; Assigned to Arm(s): 5-Fluorouracil (5-FU)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination
Brief Summary: This study will evaluate the efficacy and safety of adding bevacizumab to crossover fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer who have experienced disease progression under first line treatment with standard chemotherapy plus bevacizumab. Participants will receive chemotherapy alone, or in combination with bevacizumab. The anticipated time on study treatment is until disease progression or unacceptable toxicity occurs. Participants are allowed to continue on bevacizumab, even after stopping chemotherapy.


Options:
A: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy, Drug: Bevacizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab
B: Arm Label: Cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetuximab | Arm Label: Panitumumab; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Cetuximab | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab
C: Intervention Type: DRUG; Name: ABX-EGF; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CPT-11 and TS-1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: CPT-11, 5-FU and l-LV | Intervention Type: DRUG; Name: CPT-11 and TS-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CPT-11, 5-FU and l-LV; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind Cross Over Clinical Trial to Determine Colchicine Efficacy in Behcet's Disease
Brief Summary: Colchicine was first used in Behcet's Disease (BD), in 1977. There are controversial reports of the efficacy of Colchicine in BD. For some experts the unresponsiveness of some patients could be explained by genetic difference between the Silk Road BD and sporadic BD from other parts of the world.

To test this hypothesis (the inefficacy of colchicine in the Silk Road BD), we designed a randomized double-blind controlled crossover study in Iran, which is in the middle of the Silk Road, and has the second highest prevalence of BD in the world.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Colchicine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colchicine | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Colchicine (for 6 months) | Intervention Type: DRUG; Name: Colchicine (for 6 months); Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Colchicine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colchicine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Colchicine (for 1 month); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.


Options:
A: Arm Label: Perampanel; Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: Perampanel; Assigned to Arm(s): Perampanel | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): Placebo
B: Arm Label: Perampenal (Core Study); Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Arm Label: Placebo (Core Study); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Perampanel (Extension Phase); Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Intervention Type: DRUG; Name: Perampanel; Assigned to Arm(s): Perampanel (Extension Phase), Perampenal (Core Study) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Core Study)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: perampanel | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: perampanel | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: perampanel | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: perampanel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: perampanel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: perampanel; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Brief Summary: A study to see if better control of type 2 diabetes can occur in patients taking a stable dose of metformin when they are also provided either sitagliptin or glimepiride. This study will also see if this treatment is safe and tolerable.


Options:
A: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Sulphonylruea | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Sulphonylruea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin, Drug: Sulphonylruea | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo | Intervention Type: DRUG; Name: Sulphonylruea; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
B: Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Linagliptin Placebo | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Linagliptin Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin, Drug: open-label metformin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: glimepiride, Drug: open-label metformin | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: glimepiride; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: open-label metformin; Assigned to Arm(s): 1, 2
D: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Glibenclamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: glibenclamide, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: glibenclamide; Assigned to Arm(s): Glibenclamide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glibenclamide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide

Answer: C